Connected care enters a vital security frontier

Tern plc

As hospitals deploy more connected devices, the real vulnerability is no longer the network but the devices themselves. Device Authority is targeting this exact gap, offering a way to manage trust, identity and compliance at scale, all without manual oversight.

At the heart of the offering is automation of device trust and lifecycle management. For manufacturers and operators of connected medical equipment, the challenge lies in provisioning, rotating, revoking and monitoring credentials across large fleets, often in highly regulated settings. The KeyScaler platform is branded as delivering exactly that: seamless device registration, certificate management, enforcing Zero Trust policy at the edge, and continuous assurance of connected devices. By automating those security operations, the firm aims to reduce human error, accelerate incident response and support compliance across healthcare networks.

The company’s positioning in IoMT complements its broader IoT/OT play, suggesting opportunity for cross‑industry efficiencies. With connected medical devices trending upwards, and hospital networks under increasing pressure to secure them against threat actors and compliance breaches, the addressable market is set to expand.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search